Abraham S. Meijnikman

Abraham S. Meijnikman

Auto-generated profile, based on publicly available information

Abraham S. Meijnikman

Department of Experimental Vascular & Internal Medicine Amsterdam University Medical Centers Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
AMA. S. Meijnikman
A. S. Meijnikman
OAO. Aydin
O. Aydin
APA. Prodan
A. Prodan
VTV. Tremaroli
V. Tremaroli
HHH. Herrema
H. Herrema
MNmax Nieuwdorp
max Nieuwdorp

8 July 2020 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
COC. C. Van Olden
C. C. Van Olden
ALA. W. Van de Laar
A. W. Van de Laar
AMA. S. Meijnikman
A. S. Meijnikman
OAO. Aydin
O. Aydin
NON. Van Olst
N. Van Olst
VGVictor Gerdes
Victor Gerdes
Introduction: Prevalence of obesity and associated diseases, including type 2 diabetes mellitus, dyslipidaemia and non‐alcoholic fatty liver disease (NAFLD), are increasing. Underlying mechanisms, especially in humans, are unclear. Bariatric surgery provides the unique opportunity to obtain biopsies and portal vein blood‐samples.Methods: The BARIA Study aims to assess how microbiota and their metabolites affect transcription in key tissues and clinical outcome in obese subjects and how baseline anthropometric and metabolic characteristics determine weight loss and glucose homeostasis after bariatric surgery. We phenotype patients undergoing bariatric surgery (predominantly laparoscopic Roux‐en‐Y gastric bypass), before weight loss, with biometrics, dietary and psychological questionnaires, mixed meal test (MMT) and collect fecal‐samples and intra‐operative biopsies from liver, adipose tissues and jejunum. We aim to include 1500 patients. A subset (approximately 25%) will undergo intra‐operative portal vein blood‐sampling. Fecal‐samples are analyzed with shotgun metagenomics and targeted metabolomics, fasted and postprandial plasma‐samples are subjected to metabolomics, and RNA is extracted from the tissues for RNAseq‐analyses. Data will be integrated using state‐of‐the‐art neuronal networks and metabolic modeling. Patient follow‐up will be ten years.Results: Preoperative MMT of 170 patients were analysed and clear differences were observed in glucose homeostasis between individuals. Repeated MMT in 10 patients showed satisfactory intra‐individual reproducibility, with differences in plasma glucose, insulin and triglycerides within 20% of the mean difference.Conclusion: The BARIA study can add more understanding in how gut‐microbiota affect metabolism, especially with regard to obesity, glucose metabolism and NAFLD. Identification of key factors may provide diagnostic and therapeutic leads to control the obesity‐associated disease epidemic.

10 July 2021 in Obesity Science & Practice
Verified
Journal Article
Open access
PDF file
GBGuido J. Bakker
Guido J. Bakker
AMAbraham S. Meijnikman
Abraham S. Meijnikman
TSTorsten P. Scheithauer
Torsten P. Scheithauer
MDMark Davids
Mark Davids
ÖAÖmrüm Aydin
Ömrüm Aydin
MNmax Nieuwdorp
max Nieuwdorp
Aims: Visceral adipose tissue inflammation is a fundamental mechanism of insulin resistance in obesity and type 2 diabetes. Translocation of intestinal bacteria has been suggested as a driving factor for the inflammation. However, although bacterial DNA was detected in visceral adipose tissue of humans with obesity, it is unclear to what extent this is contamination or whether the gut microbiota is causally involved. Effects of fecal microbiota transplantation (FMT) on bacterial translocation and visceral adipose tissue inflammation in individuals with obesity and insulin resistance were assessed.Material and Methods: Eight individuals with clinically severe obesity (body mass index [BMI] >35 kg/m2) and metabolic syndrome received lean donor FMT 4 weeks prior to elective bariatric surgery. The participants were age‐, sex‐, and BMI‐matched to 16 controls that underwent no fecal transplantation. Visceral adipose tissue was collected during surgery. Bacterial translocation was assessed by 16S rRNA gene sequencing of adipose tissue and feces. Pro‐inflammatory cytokine expression and histopathological analyses of visceral adipose tissue were performed to assess inflammation.Results: Fecal microbiota transplantation significantly altered gut microbiota composition. Visceral adipose tissue contained a very low quantity of bacterial DNA in both groups. No difference in visceral bacterial DNA content between groups was observed. Also, visceral expression of pro‐inflammatory cytokines and macrophage infiltration did not differ between groups. No correlation between inflammatory tone and bacterial translocation was observed.Conclusions: Visceral bacterial DNA content and level of inflammation were not altered upon FMT. Thus, bacterial translocation may not be the main driver of visceral adipose tissue inflammation in obesity.

29 July 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
OAOluwatomisono Ikpomwosa Akinrimisi
Oluwatomisono Ikpomwosa Akinrimisi
MKMijra Koning
Mijra Koning
JSJean Scheijen
Jean Scheijen
AMAbraham S. Meijnikman
Abraham S. Meijnikman
DSDaniko P. Sindhunata
Daniko P. Sindhunata
NHNordin Hanssen
Nordin Hanssen
Introduction: Methylglyoxal (MGO) is a very reactive compound that modifies proteins, forming advanced glycation end products (AGEs) and activating inflammatory pathways. Elevated MGO levels have been linked to various diseases, including type 2 diabetes and atherosclerosis. However, the role of MGO and other glycating agents in the progression of liver fibrosis in the setting of metabolic dysfunction associated steatotic liver disease (MASLD) is poorly understood. Methods: This study explores the relationship between plasma MGO levels and related dicarbonyls (glyoxal (GO) and 3‐deoxyglucosone (3‐DG)), which are measured using ultra‐high‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS), and liver fibrosis assessed via histological liver biopsy scoring and the Fibrosis‐4 (FIB‐4) Index. The study population comprised 264 severely obese individuals due to undergo bariatric surgery, a subset from the BARIA cohort (22% type 2 diabetes; 77% females; median age 47 (IQR: 39–54 years); BMI 39 (IQR: 36–41 kg/m 2 )). Results: MGO levels were significantly higher in individuals with type 2 diabetes compared with individuals without type 2 diabetes, with a median of 288 nmol/L (257–334 nmol/L) and 238 (212–279 nmol/L) respectively. MGO levels were higher in males compared with females, with a median of 267 (236–301 nmol/L) and 245 (214–288 nmol/L) respectively. Similar results were found for GO and 3DG. Higher plasma MGO, GO and 3DG levels were significantly associated with the FIB‐4 Index (MGO, rho = 0.21, p < 0.01), (GO, rho = 0.29, p < 0.01), (3DG, rho = 0.25, p < 0.05). Using linear regression models, the association between MGO and the FIB‐4 Index remained significant after adjustment for age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels. Using ordinal logistic regression models, MGO and GO were also associated with liver fibrosis scoring from biopsy before and after adjustment for confounders (Age (years), sex, BMI, sub‐cohort, smoking status, alcohol consumption, hypertension, HOMA‐IR, HbA1c and fasting glucose levels). Notably, the relationships remained significant in individuals without type 2 diabetes and after adjusting for HbA1c and fasting glucose levels. No significant associations were observed between MGO, GO, or 3DG and steatosis or inflammation histology scores after adjustment for confounders. Conclusion: This study shows the potential role of dicarbonyl stress, particularly MGO, in liver fibrosis among obese individuals, highlighting its significance as an independent contributor to liver damage and a potential therapeutic target.